11 Jan 2021 | 10:23 am | 1 min. read
Multinational law firm Pinsent Masons advised GNA Biosolutions GmbH on IP and commercial aspects of its rapid PCR Covid-19 test.
The test, developed by German molecular diagnostics company GNA Biosolutions, has been approved by the domestic regulatory German Federal Institute for Drugs and Medical Devices (BfArM). The new PCR test, which produces a result in 40 minutes, is being rolled out across Germany with EU-wide approval expected in the coming months
The reliability of the rapid test system by GNA Biosolutions is comparable to common PCR tests, which, however, require up to 48 hours for a result.
The Pinsent Masons team advising on the deal was led by corporate partner Tobias Rodehau and included head of German public and regulatory Dr. Anke Empting, commercial and IP partner Dr. Michael Reich, technology, science and industry sector head Dr. Florian von Baum, head of German IP Marc Holtorf, and commercial legal director Dr. Igor Barabash.
Commenting on the project, Tobias Rodehau, said: "We are proud to have been able to assist GNA Biosolutions GmbH with this important project. Thanks to our expertise in the life sciences sector, we are familiar with the specifics of this industry and have been able to assemble a cross disciplinary team to play a role in facilitating swift access to this groundbreaking technology."
GNA Biosolutions GmbH is a long-standing client of Pinsent Masons. In 2019 the firm successfully advised the company on its USD 13.5 million Series C financing.
The Bavarian state government has acquired six GNA Biosolutions test devices, which were officially approved in December, as well as 60,000 test kits.
Tobias specialises in small and mid-cap private equity transactions, with a focus on venture capital transactions.
Rechtsanwältin, Partner, Head of German Public & Regulatory
Anke specialises in Public Commercial Law/Public Sector and has more than 10 years' experience in advising the public sector.
Rechtsanwalt, Partner, Sector Head Technology, Science & Industry
Florian is the Global Head of Technology, Science & Industry
Rechtsanwalt, Fachanwalt für Gewerblichen Rechtsschutz, Partner, Head of German Intellectual Property
Marc leads Pinsent Masons’ German Intellectual Property Group and the German Life Sciences sector. He specialises in supporting pharmaceutical, medical device and other high-tech companies in navigating through the complex world of contentious and non-contentious intellectual property.
Rechtsanwalt, Legal Director
Igor is a Legal Director advising German and international clients on all aspects of outsourcing, commercial, competition and technology law related matters, with a focus on companies in the life science, biotech, telecommunications and IT fields.
Multinational law firm Pinsent Masons has appointed transport and infrastructure expert Miguel Nieto, as Finance and Projects partner in Madrid where he will focus on the growing transport and mobility market.
Pay gap reporting highlights the value and importance of our drive to promote diversity and inclusion. This year we have opted to report on our disability pay gap for the first time as we underscore our commitment to belonging and inclusion and strengthen our network groups to encourage and champion change for all of our people.
Multinational law firm Pinsent Masons has advised global fund administrator Sanne Group on the first specialised depositary licence to be granted by the Central Bank of Ireland, further enhancing Sanne’s capabilities in Ireland and its multi-jurisdictional proposition for alternative fund managers.
Multinational law firm Pinsent Masons has provided the legal advice in a set of new reports recommending the latest innovation in the burgeoning technology of data trusts.
Multinational law firm Pinsent Masons has advised Teva Pharmaceuticals’ subsidiary, Actavis Group PTC, on the successful €84m sale of a suite of consumer healthcare products to Karo Pharma AB (Karo).
Multinational law firm Pinsent Masons has advised on the commercial close of four dialysis centres – a pathfinder public private partnership (PPP) implemented in Uzbekistan.
For all media enquiries, including arranging an interview with one of our spokespeople, please contact the press office on